Subjects

Abstract

Follicular lymphoma is an incurable malignancy1, with transformation to an aggressive subtype representing a critical event during disease progression. Here we performed whole-genome or whole-exome sequencing on 10 follicular lymphoma–transformed follicular lymphoma pairs followed by deep sequencing of 28 genes in an extension cohort, and we report the key events and evolutionary processes governing tumor initiation and transformation. Tumor evolution occurred through either a 'rich' or 'sparse' ancestral common progenitor clone (CPC). We identified recurrent mutations in linker histone, JAK-STAT signaling, NF-κB signaling and B cell developmental genes. Longitudinal analyses identified early driver mutations in chromatin regulator genes (CREBBP, EZH2 and KMT2D (MLL2)), whereas mutations in EBF1 and regulators of NF-κB signaling (MYD88 and TNFAIP3) were gained at transformation. Collectively, this study provides new insights into the genetic basis of follicular lymphoma and the clonal dynamics of transformation and suggests that personalizing therapies to target key genetic alterations in the CPC represents an attractive therapeutic strategy.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Accessions

Primary accessions

Gene Expression Omnibus

References

  1. 1.

    et al. Improved survival of follicular lymphoma patients in the United States. J. Clin. Oncol. 23, 5019–5026 (2005).

  2. 2.

    et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J. Clin. Oncol. 26, 5165–5169 (2008).

  3. 3.

    & Transformation of indolent B-cell lymphomas. J. Clin. Oncol. 29, 1827–1834 (2011).

  4. 4.

    et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J. Clin. Oncol. 25, 2426–2433 (2007).

  5. 5.

    et al. Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lymphoma clone. Blood 113, 3553–3557 (2009).

  6. 6.

    et al. Genomic alterations reveal potential for higher grade transformation in follicular lymphoma and confirm parallel evolution of tumor cell clones. Blood 116, 1489–1497 (2010).

  7. 7.

    et al. Sμ mutation patterns suggest different progression pathways in follicular lymphoma: early direct or late from FL progenitor cells. Blood 112, 1951–1959 (2008).

  8. 8.

    et al. Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation. Cancer Discov. 2, 47–55 (2012).

  9. 9.

    et al. EZH2 Y641 mutations in follicular lymphoma. Leukemia 25, 726–729 (2011).

  10. 10.

    et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 42, 181–185 (2010).

  11. 11.

    et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476, 298–303 (2011).

  12. 12.

    et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 471, 189–195 (2011).

  13. 13.

    et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 319, 1676–1679 (2008).

  14. 14.

    et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463, 88–92 (2010).

  15. 15.

    et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat. Genet. 43, 830–837 (2011).

  16. 16.

    et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc. Natl. Acad. Sci. USA 110, 1398–1403 (2013).

  17. 17.

    et al. Nucleosomes, linker DNA, and linker histone form a unique structural motif that directs the higher-order folding and compaction of chromatin. Proc. Natl. Acad. Sci. USA 95, 14173–14178 (1998).

  18. 18.

    , , , & Sequence-specific antirepression of histone H1–mediated inhibition of basal RNA polymerase II transcription. Science 251, 643–649 (1991).

  19. 19.

    et al. Histone H1 depletion in mammals alters global chromatin structure but causes specific changes in gene regulation. Cell 123, 1199–1212 (2005).

  20. 20.

    , & Mapping the interaction surface of linker histone H10 with the nucleosome of native chromatin in vivo. Nat. Struct. Mol. Biol. 13, 250–255 (2006).

  21. 21.

    et al. Identification of two DNA-binding sites on the globular domain of histone H5. EMBO J. 15, 3421–3429 (1996).

  22. 22.

    , , , & Crystal structure of globular domain of histone H5 and its implications for nucleosome binding. Nature 362, 219–223 (1993).

  23. 23.

    & N- and C-terminal domains determine differential nucleosomal binding geometry and affinity of linker histone isotypes H10 and H1c. J. Biol. Chem. 287, 11778–11787 (2012).

  24. 24.

    et al. Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset of B-cell lymphoma entities. Blood 114, 4503–4506 (2009).

  25. 25.

    et al. Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma. Blood 114, 1236–1242 (2009).

  26. 26.

    et al. STAT6 and STAT1 are essential antagonistic regulators of cell survival in classical Hodgkin lymphoma cell line. Leukemia 23, 1885–1893 (2009).

  27. 27.

    , , , & Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6. Blood 110, 3387–3390 (2007).

  28. 28.

    et al. STAT6 activity is regulated by SOCS-1 and modulates BCL-XL expression in primary mediastinal B-cell lymphoma. Leukemia 22, 2106–2110 (2008).

  29. 29.

    et al. Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma. Nature 459, 717–721 (2009).

  30. 30.

    et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 470, 115–119 (2011).

  31. 31.

    et al. Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood 116, 4874–4884 (2010).

  32. 32.

    , , , & Cloning and functional characterization of early B-cell factor, a regulator of lymphocyte-specific gene expression. Genes Dev. 7, 760–773 (1993).

  33. 33.

    , , & Structure of an Ebf1:DNA complex reveals unusual DNA recognition and structural homology with Rel proteins. Genes Dev. 24, 2270–2275 (2010).

  34. 34.

    et al. Early B cell factor 1 regulates B cell gene networks by activation, repression, and transcription-independent poising of chromatin. Immunity 32, 714–725 (2010).

  35. 35.

    et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413–421 (2012).

  36. 36.

    et al. Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood 121, 1604–1611 (2013).

  37. 37.

    et al. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N. Engl. J. Med. 367, 826–833 (2012).

  38. 38.

    et al. High-resolution mapping of H1 linker histone variants in embryonic stem cells. PLoS Genet. 9, e1003417 (2013).

  39. 39.

    & Genetic analysis of H1 linker histone subtypes and their functions in mice. Methods Enzymol. 377, 85–107 (2004).

  40. 40.

    et al. A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients. Exp. Hematol. 29, 183–193 (2001).

  41. 41.

    et al. Allele-specific copy number analysis of tumors. Proc. Natl. Acad. Sci. USA 107, 16910–16915 (2010).

  42. 42.

    et al. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics 28, 1811–1817 (2012).

  43. 43.

    & Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754–1760 (2009).

  44. 44.

    et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43, 491–498 (2011).

  45. 45.

    , & SNPnexus: a web server for functional annotation of novel and publicly known genetic variants (2012 update). Nucleic Acids Res. 40, W65–W70 (2012).

  46. 46.

    et al. VarScan2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22, 568–576 (2012).

  47. 47.

    , , & Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5, 557–572 (2004).

  48. 48.

    , , , & Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics 25, 2865–2871 (2009).

  49. 49.

    et al. DELLY: structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics 28, i333–i339 (2012).

  50. 50.

    et al. BreakDancer: an algorithm for high-resolution mapping of genomic structural variation. Nat. Methods 6, 677–681 (2009).

  51. 51.

    & The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol. Biol. Evol. 4, 406–425 (1987).

  52. 52.

    & Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357–359 (2012).

  53. 53.

    et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078–2079 (2009).

  54. 54.

    & Chronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomics. Genome Med. 5, 47 (2013).

  55. 55.

    et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 412, 341–346 (2001).

  56. 56.

    et al. Recurrent targets of aberrant somatic hypermutation in lymphoma. Oncotarget 3, 1308–1319 (2012).

  57. 57.

    et al. Histone H1 depletion impairs embryonic stem cell differentiation. PLoS Genet. 8, e1002691 (2012).

  58. 58.

    , , & Expression analysis of mammalian linker-histone subtypes. J. Vis. Exp. 61, e3577 (2012).

Download references

Acknowledgements

We are indebted to the patients for donating tumor specimens as part of this study. We would like to thank T. Chaplin-Perkins and B. Young for performing the SNP 6.0 array experiments as part of the Affymetrix Array Core Facility and G. Clark at the London Research Institute for automated DNA sequencing. This study was predominantly funded by Cancer Research UK through the Genomic Initiative and Programme grant (15968) to J.F. and was also supported by Leukemia and Lymphoma Research (grant to J.F.) and Hungarian Scientific Research Fund (Országos Tudományos Kutatási Alapprogramok, OTKA) grant K-76204 (to A.M.). Y.F. is a recipient of the Georgia Cancer Coalition Distinguished Scholar Award, and C.P. and Y.F. are, in part, supported by US National Institutes of Health grant GM085261 (to Y.F.). C.B. is a recipient of the European Hematology Association (EHA) Partner fellowship (2009/1) and was supported by the European Union and the State of Hungary, cofinanced by the European Social Fund in the framework of TÁMOP 4.2.4. A/1-11-1-2012-0001 National Excellence Program. J.O. is a recipient of the Kay Kendall Leukaemia Fund (KKLF) Junior Clinical Research Fellowship (KKL 557).

Author information

Author notes

    • Jessica Okosun
    • , Csaba Bödör
    •  & Jun Wang

    These authors contributed equally to this work.

Affiliations

  1. Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.

    • Jessica Okosun
    • , Csaba Bödör
    • , Shamzah Araf
    • , Sameena Iqbal
    • , Janet Matthews
    • , David Wrench
    • , Kiran Tawana
    • , Nikolay Popov
    • , Ciaran O'Riain
    • , Derville O'Shea
    • , Emanuela Carlotti
    • , Maria Calaminici
    • , T Andrew Lister
    • , Silvia Montoto
    • , John G Gribben
    •  & Jude Fitzgibbon
  2. 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.

    • Csaba Bödör
    •  & András Matolcsy
  3. Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.

    • Jun Wang
    • , Jacek Marzec
    •  & Claude Chelala
  4. Department of Cellular and Molecular Immunology, Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.

    • Cheng-Yuan Yang
    • , Sören Boller
    •  & Rudolf Grosschedl
  5. School of Biology, Georgia Institute of Technology, Atlanta, Georgia, USA.

    • Chenyi Pan
    •  & Yuhong Fan
  6. Parker H. Petit Institute for Bioengineering and Biosciences, Georgia Institute of Technology, Atlanta, Georgia, USA.

    • Chenyi Pan
    •  & Yuhong Fan
  7. Centre for Translational Genomics and Bioinformatics, San Raffaele Scientific Institute, Milan, Italy.

    • Davide Cittaro
    •  & Elia Stupka
  8. Genome Centre, Barts and the London School of Medicine and Dentistry, London, UK.

    • Monika Bozek
    •  & Charles Mein
  9. Cancer Sciences Division, University of Southampton, Southampton, UK.

    • Andrew Davies
  10. Oncology Department, Biodonostia Research Institute, San Sebastian, Spain.

    • Charles H Lawrie
  11. Department of Histopathology, Christie National Health Service (NHS) Foundation Trust, Manchester, UK.

    • Andrew Norton
  12. Department of Histopathology, Manchester Royal Infirmary, Manchester, UK.

    • Richard J Byers
  13. Department of Hematology, Oncology and Tumor Immunology, Charité Universitätsmedizin, Berlin, Germany.

    • Georg Lenz

Authors

  1. Search for Jessica Okosun in:

  2. Search for Csaba Bödör in:

  3. Search for Jun Wang in:

  4. Search for Shamzah Araf in:

  5. Search for Cheng-Yuan Yang in:

  6. Search for Chenyi Pan in:

  7. Search for Sören Boller in:

  8. Search for Davide Cittaro in:

  9. Search for Monika Bozek in:

  10. Search for Sameena Iqbal in:

  11. Search for Janet Matthews in:

  12. Search for David Wrench in:

  13. Search for Jacek Marzec in:

  14. Search for Kiran Tawana in:

  15. Search for Nikolay Popov in:

  16. Search for Ciaran O'Riain in:

  17. Search for Derville O'Shea in:

  18. Search for Emanuela Carlotti in:

  19. Search for Andrew Davies in:

  20. Search for Charles H Lawrie in:

  21. Search for András Matolcsy in:

  22. Search for Maria Calaminici in:

  23. Search for Andrew Norton in:

  24. Search for Richard J Byers in:

  25. Search for Charles Mein in:

  26. Search for Elia Stupka in:

  27. Search for T Andrew Lister in:

  28. Search for Georg Lenz in:

  29. Search for Silvia Montoto in:

  30. Search for John G Gribben in:

  31. Search for Yuhong Fan in:

  32. Search for Rudolf Grosschedl in:

  33. Search for Claude Chelala in:

  34. Search for Jude Fitzgibbon in:

Contributions

J.F., J.O. and C.B. designed and directed the study. J.O. and J.F. wrote the manuscript. T.A.L., S.M., J. Matthews and. J.G.G. identified patients for the study. and collected clinical information. S.I. prepared DNA samples. M.C., A.N., A.M. and R.J.B. conducted pathological review of specimens. J.W., D.C., J. Marzec, E.S., G.H.L., G.M. and C.C. performed the bioinformatic analysis. J.O., C.B., S.A., C.-Y.Y., S.B., C.P., M.B., D.W., K.T., N.P., C.O., D.O., E.C. and A.D. performed experiments. J.O., J.W., C.B., S.A., C.-Y.Y., S.B., G.L., Y.F. and R.G. analyzed the data. All authors read, critically reviewed and approved the manuscript.

Competing interests

The authors declare no competing financial interests.

Corresponding authors

Correspondence to Jessica Okosun or Csaba Bödör.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Note, Supplementary Figures 1–14 and Supplementary Table 1

Excel files

  1. 1.

    Supplementary Tables 2–13

    Supplementary Tables 2–13

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/ng.2856

Further reading